RMTI - Rockwell Medical, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

RMTI

ROCKWELL MEDICAL, INC.

NASDAQ

$7.78

▼ DOWN 2.26% (-0.18)

KEY STATISTICS

Market Cap$31.42 M

52w High$17.20

52w Low$4.89

Dividend Yield—

Frequency—

P/E-5.81

Volume5.90K

Shares Out.3.95M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Mark Strobeck

COMPENSATION 2026

Salary$566,500

Stock Awards$612,040

Incentive Plan Pay$453,200

All Other Comp.$14,000

Total$1,895,472

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 27, 1998

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

157

PRICE TARGET

Target High$20.00

Target Low$20.00

Target Median$20.00

Target Consensus$20.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$18.22M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-07-01	Reverse	1:10
2022-05-13	Reverse	1:11

PRICE

$7.78 ▼ DOWN 2.26% (−$0.18)

OVERLAYS

About Rockwell Medical, Inc.

https://www.rockwellmed.com ↗

Rockwell Medical, Inc. develops therapies and products for end-stage renal and chronic kidney disease, including iron therapies and dialysis concentrates, serving dialysis centers and developing treatments for acute heart failure and home infusion.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT ROCKWELL MEDICAL, INC. IS KNOWN FOR

RenalPure® and SteriLyte® Hemodialysis Concentrates Convenience Pack

Rockwell Medical's new RenalPure® and SteriLyte® packaging focus on concentrates for at-home and acute dialysis, highlighted by a September 2024 US provider agreement, emphasizing their growth in the dialysis concentrates market.